share_log

Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Addex Therapeutics | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/06/06 05:07

Moomoo AI 已提取核心信息

Addex Therapeutics reported Q1 2024 financial results with revenue of CHF 0.2M from the Indivior collaboration, down from CHF 0.5M in Q1 2023. Operating costs increased to CHF 1.0M from CHF 0.9M, primarily due to higher legal fees. Net loss from continuing operations was CHF 0.7M compared to CHF 0.4M in Q1 2023.On April 2, 2024, Addex completed the sale of its allosteric modulator drug discovery platform and preclinical portfolio to newly formed Neurosterix Pharma, which received USD 63M funding led by Perceptive Advisors. Addex received CHF 5M cash and retained 20% equity in Neurosterix. The company maintains partnerships with Janssen and Indivior, along with clinical-stage assets including dipraglurant.Cash and cash equivalents stood at CHF 1.6M as of March 31, 2024, compared to CHF 3.9M at year-end 2023. The company recorded CHF 0.8M in assets held for sale and CHF 1.3M in associated liabilities related to the Neurosterix transaction.
Addex Therapeutics reported Q1 2024 financial results with revenue of CHF 0.2M from the Indivior collaboration, down from CHF 0.5M in Q1 2023. Operating costs increased to CHF 1.0M from CHF 0.9M, primarily due to higher legal fees. Net loss from continuing operations was CHF 0.7M compared to CHF 0.4M in Q1 2023.On April 2, 2024, Addex completed the sale of its allosteric modulator drug discovery platform and preclinical portfolio to newly formed Neurosterix Pharma, which received USD 63M funding led by Perceptive Advisors. Addex received CHF 5M cash and retained 20% equity in Neurosterix. The company maintains partnerships with Janssen and Indivior, along with clinical-stage assets including dipraglurant.Cash and cash equivalents stood at CHF 1.6M as of March 31, 2024, compared to CHF 3.9M at year-end 2023. The company recorded CHF 0.8M in assets held for sale and CHF 1.3M in associated liabilities related to the Neurosterix transaction.
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Corcept医疗
    CORT
    -- 114.220
    ABVC BioPharma
    ABVC
    -- 1.0600
    bluebird bio
    BLUE
    -- 4.880
    NLS Pharmaceutics
    NLSP
    -- 1.5400
    DBV Technologies
    DBVT
    -- 6.820
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日